Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has granted stock options to six new non-executive employees under its 2022 Employment Inducement Award Plan. The equity awards, approved on September 13, 2024, comply with Nasdaq Listing Rule 5635(c)(4). In total, the new employees received options to purchase 1,015,000 shares of Annexon common stock. These options have a ten-year term and an exercise price of $7.20 per share, matching the closing price of Annexon's stock on the grant date. The options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly, subject to continued employment.
Annexon (Nasdaq: ANNX), un'azienda biofarmaceutica focalizzata nello sviluppo di nuove terapie complementari per le malattie neuroinfiammatorie, ha concesso opzioni su azioni a sei nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivazione all'Occupazione 2022. Gli premi azionari, approvati il 13 settembre 2024, rispettano la Regola di Quotazione Nasdaq 5635(c)(4). In totale, i nuovi dipendenti hanno ricevuto opzioni per acquistare 1.015.000 azioni ordinarie di Annexon. Queste opzioni hanno un termine di dieci anni e un prezzo di esercizio di 7,20 dollari per azione, corrispondente al prezzo di chiusura delle azioni di Annexon alla data di concessione. Le opzioni maturano in 4 anni, con il 25% che matura dopo un anno e il resto che matura mensilmente, subordinato alla continuazione del rapporto di lavoro.
Annexon (Nasdaq: ANNX), una empresa biofarmacéutica centrada en desarrollar nuevas terapias complementarias para enfermedades neuroinflamatorias, ha otorgado opciones sobre acciones a seis nuevos empleados no ejecutivos bajo su Plan de Incentivo de Empleo de 2022. Las concesiones de acciones, aprobadas el 13 de septiembre de 2024, cumplen con la Regla de Cotización Nasdaq 5635(c)(4). En total, los nuevos empleados recibieron opciones para comprar 1.015.000 acciones ordinarias de Annexon. Estas opciones tienen un plazo de diez años y un precio de ejercicio de 7,20 dólares por acción, igualando el precio de cierre de las acciones de Annexon en la fecha de otorgamiento. Las opciones se consolidan en 4 años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente, sujeto a la continuidad del empleo.
Annexon (Nasdaq: ANNX), 신경 염증 질환에 대한 새로운 보완 치료제를 개발하는 데 중점을 둔 생물 제약 회사는 여섯 명의 새로운 비상무 직원에게 주식 옵션을 부여했습니다 2022 고용 유도 보상 계획 하에. 2024년 9월 13일 승인된 주식 보상은 나스닥 상장 규칙 5635(c)(4)를 준수합니다. 총 새 직원들은 1,015,000주를 구매할 수 있는 옵션을 받았습니다. 이 옵션은 10년의 기간과 주당 7.20달러의 행사 가격을 가지고 있으며, 이는 부여일에 Annexon 주식의 종가와 일치합니다. 옵션은 4년에 걸쳐 귀속됩니다, 1년 후 25%가 귀속되고 나머지는 계속 고용 조건에 따라 매월 귀속됩니다.
Annexon (Nasdaq: ANNX), une société biopharmaceutique axée sur le développement de nouvelles thérapies complémentaires pour les maladies neuro-inflammatoires, a accordé des options sur actions à six nouveaux employés non exécutifs dans le cadre de son Plan de Récompense pour l'Emploi 2022. Les attributions en actions, approuvées le 13 septembre 2024, sont conformes à la Règle de Cotation Nasdaq 5635(c)(4). Au total, les nouveaux employés ont reçu des options pour acheter 1.015.000 actions ordinaires d'Annexon. Ces options ont une durée de dix ans et un prix d'exercice de 7,20 $ par action, équivalant au prix de clôture des actions d'Annexon à la date d'attribution. Les options s'acquièrent sur 4 ans, avec 25 % qui s'acquièrent après un an et le reste qui s'acquiert mensuellement, sous réserve de la poursuite de l'emploi.
Annexon (Nasdaq: ANNX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Komplementtherapien für neuroinflammatorische Erkrankungen konzentriert, hat sechs neuen nicht-executiven Mitarbeitern Aktienoptionen gewährt im Rahmen seines Anreizplans zur Beschäftigung 2022. Die Eigenkapitalvergaben, die am 13. September 2024 genehmigt wurden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Insgesamt erhielten die neuen Mitarbeiter Optionen zum Kauf von 1.015.000 Stammaktien von Annexon. Diese Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 7,20 $ pro Aktie, der dem Schlusskurs der Annexon-Aktien am Tag der Gewährung entspricht. Die Optionen verfallen über 4 Jahre, wobei 25 % nach einem Jahr und der Rest monatlich fällig wird, sofern die Anstellung fortgesetzt wird.
- Annexon is attracting new talent, potentially strengthening its workforce
- The company is offering competitive stock options to new employees, aligning their interests with shareholders
- Granting of stock options may lead to potential dilution for existing shareholders
BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 13, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 1,015,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon’s novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
How many new employees received stock options from Annexon (ANNX) on September 13, 2024?
What is the total number of Annexon (ANNX) stock options granted to new employees?
What is the exercise price of the stock options granted by Annexon (ANNX) on September 13, 2024?
What is the vesting schedule for the stock options granted by Annexon (ANNX) to new employees?
